Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Corporate Update (Jan 8, 2024)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed January 8, 2024
Period End
January 8, 2024
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · May ’23May ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 8-K filed January 8, 2024. Cited figures are marked; the original filing is the authoritative source.

On January 8, 2024, BridgeBio Pharma, Inc. filed a Form 8-K under Item 8.01 (Other Events) to furnish its slides from a business update presented at the 42nd Annual J.P.

Morgan Healthcare Conference. The filing itself is brief; its substance is in Exhibit 99.1, the presentation slides. The company's main near-term focus is the launch of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM), for which it states a新 Drug Application was submitted to the FDA in November 2023 and an anticipated FDA approval and commercial launch in 2H 2024.

The presentation describes preliminary ATTRibute-CM data, including separation in composite survival and hospitalization outcomes at 3 months and preliminary amyloid regression on cardiac MRI imaging, and states that comprehensive analyses are expected in 2024. Management says the company has hired a commercial team with cardiovascular experience and cites independent market research estimating 25-40%a market share for acoramidis in a future four-product market. The slides also cite an ATTR-CM market growing at approximately 15% quarter-on-quarter and an EU Opposition Division decision expected to keep Vyndaqel's market exclusivity through August 2035.

Beyond ATTR-CM, the slides update the pipeline: infigratinib for achondroplasia (Phase 3, with last patient in expected in 1H 2024 and study completion in 2025), BBP-418 for LGMD2I (interim analysis in 1H 2025), encaleret for ADH1 (Phase 3 readout expected early 2025, with enrollment described as behind schedule earlier but now progressing), and BBP-631 for congenital adrenal hyperplasia (Phase 2, with Cohort 4 dosing commenced and initial data expected in Q3 2024). The company reported $560 millionb of cash and equity investments as of its last earnings report dated November 2, 2023.

Key Highlights

  1. Acoramidis (ATTR-CM): NDA submitted to the FDA in November 2023; anticipated FDA approval and commercial launch in 2H 2024, with the company aiming to make it the backbone of ATTR-CM treatment.
  2. Preliminary ATTRibute-CM data show early separation in composite all-cause mortality and cardiovascular hospitalization at 3 months, and preliminary cardiac MRI evidence of amyloid regression in an acoramidis-treated patient, with comprehensive analyses to come in 2024.
  3. Market research cited in the slides estimates 25-40% acoramidis market share in a future four-product market, and the tafamidis prescriber base is described as growing 30-50% annually.
  4. EU patent: the Opposition Division upheld Pfizer's tafamidis patent claims, with the company setting the expectation that Vyndaqel will maintain market exclusivity through August 2035.
  5. Pipeline: infigratinib for achondroplasia (Phase 3, $5Bn total addressable market, study completion expected 2025); BBP-418 for LGMD2I (Phase 3, interim analysis 1H 2025); encaleret for ADH1 (Phase 3 readout expected early 2025).
  6. BBP-631 for congenital adrenal hyperplasia (Phase 2, $2Bn+ addressable market): early data show increases in 11-deoxycortisol, and Cohort 4 at 1.2e14 vg/kg has begun dosing with initial data expected in Q3 2024.
  7. Liquidity: the company cited $560 million of cash and equity investments as of its last earnings report dated November 2, 2023, comprising $522 million in cash, cash equivalents and short-term restricted cash and $38 million in equity securities investments.

Frequently Asked Questions

  1. When is acoramidis expected to launch?

    The slides state that the company submitted a New Drug Application to the FDA in November 2023 and anticipates FDA approval and commercial launch in 2H 2024. The company also plans to submit additional regulatory filings to the EMA and others in 2024.

  2. What do the early ATTRibute-CM results show?

    The company presented preliminary analyses showing acoramidis separated from placebo in composite all-cause mortality and cardiovascular hospitalization as early as 3 months, and reported preliminary amyloid regression on cardiac MRI in one acoramidis-treated patient versus progression in a placebo patient. The company states these are preliminary (modeled) analyses, with comprehensive analyses to come in 2024.

  3. What market share does the company expect for acoramidis?

    The slides cite independent market research estimating 25-40% market share for acoramidis in a future four-product ATTR-CM market, with ranges from three research methods of 27-40%, 25-30% and 25-29%. The company states it expects acoramidis to command significant share regardless of potential positive knockdown data in 2024.

  4. What are the key pipeline milestones for 2024 and 2025?

    The company expects Phase 3 enrollment completion for infigratinib in 1H 2024 with study completion in 2025, Phase 3 enrollment completion for BBP-418 in 1H 2024 with an interim analysis in 1H 2025, and an encaleret Phase 3 readout in early 2025. For BBP-631, initial data from Cohort 4 are expected in Q3 2024, and the company will make a go/no-go decision on its CAH program.

  5. How much cash does the company have?

    The company cited $560 million of cash and equity investments as of its last earnings report dated November 2, 2023, consisting of $522 million in cash, cash equivalents and short-term restricted cash and $38 million of equity securities investments as of the end of the third quarter.